Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 30, No. 4, 2010
Issue release date: October 2010
Section title: Original Research Article
Free Access
Dement Geriatr Cogn Disord 2010;30:344–351

Baseline Predictors of Clinical Progression among Patients with Dysexecutive Mild Cognitive Impairment

Johnson J.K.a–c · Pa J.c · Boxer A.L.c · Kramer J.H.c · Freeman K.c · Yaffe K.c–e
aInstitute for Health and Aging, and Departments of bSocial and Behavioral Sciences, cNeurology, and dPsychiatry, Epidemiology and Biostatistics, University of California, and eVeteran’s Affairs Medical Center, San Francisco, Calif., USA
email Corresponding Author

Julene K. Johnson, PhD

UCSF Institute for Health and Aging

3333 California St., Suite 340

San Francisco, CA 94148 (USA)

Tel. +1 415 476 1106, Fax +1 415 502 5208, E-Mail Julene.Johnson@ucsf.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background/Aims: There are few studies that evaluate the clinical outcomes of individuals with non-amnestic mild cognitive impairment (MCI). The purpose of this study was to evaluate baseline predictors of clinical progression after 2 years for patients with dysexecutive MCI (dMCI), a single-domain non-amnestic MCI subgroup. Methods:We evaluated clinical progression in a sample of 31 older adults with dMCI. Clinical progression was defined as a worsening on the Clinical Dementia Rating sum of boxes at the 2-year visit, whereas patients were classified as stable if the score did not worsen over 2 years. We compared baseline brain MRI, neuropsychological tests, and health risk factors. Results: Twelve individuals with dMCI progressed clinically, and 19 individuals remained stable over 2 years. Compared to the stable dMCI patients, the dMCI patients who progressed showed brain atrophy in the bilateral insula and left lateral temporal lobe on MRI. dMCI patients who progressed were also older, had lower baseline performance on category fluency and a spatial location task, and reported fewer dysexecutive symptoms. Health risk factors, except hypertension, did not differ between groups. Conclusion: The results suggest that dMCI patients who progress relatively quickly over 2 years may have unique clinical and brain MRI features.

© 2010 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Published online: October 12, 2010
Issue release date: October 2010

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 4

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.